Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00826449
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dasatinib — DRUG
    Starting dose of 70 mg by mouth daily for 21 day cycle.
  • Erlotinib — DRUG
    150 mg by mouth daily every 21 day cycle.

Study Details

The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when given to patients with non-small cell lung cancer. The safety of this combination will be studied in both phases.

Key Dates

First listed
Jan 22, 2009
Start date
Feb 28, 2009
Status verified
May 2016
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014

Study Design

Enrollment
53 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase I
    Dasatinib + Erlotinib

Primary Outcome Measure

Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride [ Time Frame: Baseline and at Day 21 ]

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies